Lamivudine Normon (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics the natural nucleoside deoxycytidine triphosphate. When HIV reverse transcriptase incorporates lamivudine triphosphate into viral DNA, it terminates the DNA chain, preventing further synthesis of viral genetic material and thereby inhibiting viral replication.

The prescribed dose of lamivudine is determined by the treating physician based on the specific indication, patient weight, renal function, and any concomitant medications. Dosage regimens may differ for HIV infection versus chronic hepatitis B, and adjustments are made for patients with impaired kidney function.

Lamivudine may be used during pregnancy only when the potential benefit to the mother outweighs any possible risk to the fetus. Data are limited, and the decision should be made by a healthcare professional. Breastfeeding is not recommended unless the benefit to the mother justifies potential exposure to the infant.

To place an order, submit an enquiry on the Lamivudine Normon product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other NRTIs or agents from different classes for synergistic effect. Compared with older NRTIs such as zidovudine, lamivudine generally has a more favorable safety profile, fewer mitochondrial toxicities, and is active against both HIV and hepatitis B.

Lamivudine tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister or bottle to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lamivudine is taken orally, usually with or without food, as a tablet swallowed whole with water. The exact timing and frequency are prescribed by the treating clinician and should be adhered to for optimal antiviral effect.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity, pancreatitis, hypersensitivity reactions such as Stevens‑Johnson syndrome, and significant neutropenia. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, severe fatigue, jaundice, or skin blistering.

Lamivudine is contraindicated in patients with known hypersensitivity to lamivudine or any of its excipients. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in patients receiving contraindicated drug combinations such as didanosine without appropriate monitoring.